PRISM MarketView

Lexaria to Advance CBD Hypertension Candidate with IND Approval

New York, N.Y., March 01, 2024 - PRISM MarketView - Lexaria Bioscience (Nasdaq: LEXX) continues to advance its CBD-based candidate for hypertension with the clearance of its investigational new drug (IND) application by the FDA this week. The company is now planning to i...

1 March 2024

A Look at AI in EV: indie Semiconductor (INDI) Charges Ahead, Electrifies on Earnings, Engages AI Partnership

New York, N.Y., March 01, 2024 - PRISM MarketView - Indie Semiconductor, Inc. (INDI) is an automotive software solutions and semiconductor company has been also known for accelerating vehicle electrification and recently reported Q4 earnings last week citing a record $70...

1 March 2024

Establishment Labs Holdings (ESTA) Has Almost Doubled Its Share Price Since Its PRISM Women’s Health Index Debut, Two Months Ago

New York, N.Y., February 29, 2024 - PRISM MarketView - Not only is Establishment Labs Holdings Inc. (ESTA) up 24% today, it’s also been steadily rising since the start of the year. The company who has been included in the PRISM Women’s Health Index since the indices’ inc...

29 February 2024

Enveric Biosciences Advances Mental Health Treatment, Shares Soar 127% with Out-Licensing of Compound Classes

New York, N.Y., February 29, 2024 - PRISM MarketView - Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for mental health conditions announced the signing of three non-binding term sheets with ...

29 February 2024

Someone Check Its Pulse. LivePerson, Inc. (LPSN) Shares Drop 42% On Q4 Loss and Missed Estimates

New York, N.Y., February 29, 2024 - PRISM MarketView - LivePerson, Inc. (LPSN) needs some resuscitation as it drags the PRISM NextGen Tech & AI Index today as its largest detractor, down ~42%. The company announced Q4 earnings reporting a quarterly loss of $0.18 per ...

29 February 2024

Polestar Automotive Secures $950 Million in Funding Amid Business Plan Progress; Shares Close up 22%

New York, N.Y., February 29, 2024 - PRISM MarketView - Polestar Automotive Holding UK PLC (Nasdaq: PSNY) has announced securing $950 million through a three-year loan facility provided by a syndicate of 12 international banks, including notable names like BNP Paribas and...

29 February 2024

Incannex’s Psilocybin Targets Anxiety with Positive Topline Results

New York, N.Y., February 29, 2024 - PRISM MarketView - Leading cannabinoid and psychedelic medicine biotechnology company, Incannex Healthcare (Nasdaq: IXHL), has achieved positive topline results in its Phase 2 clinical trial of psilocybin in generalized anxiety disord...

29 February 2024

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

NEW YORK, N.Y., February 29, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million Americans.

29 February 2024

Investors Are Having a Cow. Plant-Based Beyond Meat (BYND) Exceeds Q4 Revenue Estimates, Promises to Steeply Cut Costs

New York, N.Y., February 28, 2024 - PRISM MarketView - PRISM Zombie Index Leader Beyond Meat, Inc. (BYND), is seeing a big gain today as its trading close to 45% higher on its recent earnings release. However, outside of exceeding the Street’s Q4 revenue estimates ($73.7...

28 February 2024

MindMed Closes Out 2023 with Positive Phase 2b Results for Generalized Anxiety Treatment

New York, N.Y., February 28, 2024 - PRISM MarketView - Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) has announced its financial results for the year ended December 31, 2023, closing out a “highly productive” year with positive Phase 2b results for MM120 in the treatment o...

28 February 2024